Finally, although several growth factors regulate angiogenesis in PCa, most of the preclinical studies and clinical trials have been undertaken with anti-VEGFA or anti-VEGFR agents, which demonstrated modest clinical response and severe AE in patients. Here, VEGFA is linked to posterior cortical atrophy.